MFC-luc Orthotopic Mouse Model Service for Gastric Cancer

The MFC-luc orthotopic mouse model of gastric cancer unites the tissue-specific tumor microenvironment of orthotopic implantation with the quantitative, non-invasive readout of bioluminescence imaging, allowing primary gastric tumor growth and metastatic spread to be tracked longitudinally in living animals. Alfa Cytology delivers this model as a complete preclinical service — spanning luciferase-labeled cell expansion and quality control, surgical orthotopic implantation, scheduled in vivo bioluminescence imaging, customized dosing regimens, and full endpoint histopathology — so your gastric cancer programs can be evaluated in a translationally relevant, immunocompetent setting.

Overview of MFC-luc Orthotopic Mouse Model for Gastric Cancer

Gastric cancer remains one of the leading causes of cancer-related mortality worldwide, and most patients ultimately die from metastatic disease rather than the primary tumor itself. Orthotopic models, in which tumor cells are implanted directly into the organ from which the cancer originates, are therefore regarded as more physiologically informative than conventional subcutaneous xenografts: the tumor cells engage with the native stroma, vasculature, and immune milieu of the stomach, and disseminate along routes that more closely mirror clinical disease. The MFC-luc model is built on the MFC (mouse forestomach carcinoma) cell line, a murine gastric carcinoma line originally established from an N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)-induced tumor arising in an inbred 615 mouse. Because the cells are of mouse origin, they can be transplanted into immunocompetent syngeneic hosts, preserving intact tumor–immune interactions that immunodeficient platforms cannot reproduce.

Fig 1. Orthotopic MFC/MFC-Luc gastric cancer model established by direct gastric wall implantation, enabling longitudinal IVIS monitoring and evaluation of localized antitumor therapy. (Chen, Aoxing, et al., 2024)

In the MFC-luc derivative, MFC cells are stably engineered to express firefly luciferase, which catalyzes the oxidation of D-luciferin and emits photons detectable through intact tissue with a highly sensitive charge-coupled device camera. After orthotopic inoculation into the gastric wall or subserosa, this reporter permits longitudinal, quantitative monitoring of tumor burden in vivo, with signal intensity correlating with viable tumor cell numbers. MFC-derived tumors form with high penetrance and can progress to regional lymph node involvement, peritoneal seeding, and spontaneous lung metastasis, making the MFC-luc orthotopic model a practical platform for interrogating gastric tumor progression, benchmarking chemotherapeutic and immunotherapeutic agents, and dissecting the mechanisms of metastasis and immune evasion within a fully immunocompetent host.

Cell Line Information: MFC-luc

MFC is a murine gastric carcinoma cell line originally established in 1987 from a chemically induced forestomach carcinoma arising in an inbred 615 mouse, and MFC-luc is a firefly luciferase-expressing derivative generated for bioluminescence-based in vivo tracking. The cells grow as adherent monolayers, form tumors after both orthotopic and subcutaneous implantation in syngeneic hosts, and are widely used in preclinical studies of gastric tumor growth, metastasis, and treatment response.

Our Services

With extensive hands-on experience in orthotopic surgery and in vivo oncology pharmacology, Alfa Cytology has refined each stage of the MFC-luc gastric cancer workflow — from stringent cell line authentication and mycoplasma screening to standardized surgical implantation, scheduled bioluminescence imaging, and comprehensive endpoint analysis — so that every study starts from a validated, reproducible foundation. Our preclinical team works closely with you to align model parameters, dosing schedules, and readouts with your therapeutic hypothesis, delivering dependable data packages that shorten the path from candidate selection to in vivo proof-of-concept.

Workflow of MFC-luc Orthotopic Mouse Model Construction

Constructing the MFC-luc orthotopic gastric cancer model is a coordinated, multi-stage process that couples rigorous cell line quality control with precision microsurgery and longitudinal molecular imaging. The workflow below outlines the key stages, each executed under standardized operating procedures to ensure reproducibility across cohorts.

1. Reporter verification and cell banking: A luminescence assay confirms that MFC-luc cells express a strong, stable luciferase signal across passages, and master cell banks are screened for mycoplasma contamination and identity before expansion.
2. Cell expansion and inoculum preparation: Cells are expanded in vitro under standardized culture conditions, harvested at optimal confluency, counted, and resuspended at the target concentration (for example, 1×10⁶ cells in a minimal injection volume).
3. Host mouse preparation: Syngeneic recipient mice are acclimatized, randomized by body weight, and prepared in a sterile surgical field with appropriate anesthesia and perioperative analgesia.
4. Orthotopic implantation: A small laparotomy exposes the stomach, and the MFC-luc cell suspension is gently injected into the gastric subserosa of the greater curvature; the serosa is inspected for leakage before the abdominal wall is closed in layers.
5. Post-operative recovery and baseline imaging: Mice recover under warming with close clinical monitoring, and once fully stabilized, D-luciferin is administered and baseline bioluminescence images are acquired to confirm successful engraftment.
6. Longitudinal monitoring and study randomization: Tumor bioluminescence is measured on a regular schedule alongside body weight and clinical signs, and mice are randomized into treatment cohorts based on photon flux or tumor signal to minimize baseline bias.
7. Endpoint analysis: At study termination, mice undergo complete necropsy: primary gastric tumors are excised and weighed, metastatic organs are inspected and imaged ex vivo, and tissues are preserved for histopathology and downstream molecular analysis.

Fig 2. MFC-luc orthotopic mouse model construction workflow.

Case Study-MFC-luc Orthotopic Mouse Model Development

Alfa Cytology has applied the MFC-luc orthotopic gastric cancer model in multiple preclinical research programs, supporting clients in evaluating novel therapeutic candidates and combination strategies against orthotopically grown gastric tumors. In these studies, longitudinal bioluminescence tracking has been used to follow tumor burden over time, guide treatment scheduling, and quantify therapeutic response, while terminal necropsy and histopathological examination have provided confirmatory evidence of antitumor activity and metastatic status. Depending on program needs, readouts can be further extended to immune profiling and molecular analyses of tumor tissue, offering a flexible data package that adapts to each research objective. Detailed case examples and customized study data can be shared upon inquiry.

Why Choose Alfa Cytology?

Selecting the right CRO partner determines the quality and interpretability of your in vivo data. Alfa Cytology combines a validated orthotopic platform with disciplined study execution and transparent communication, giving you a dependable preclinical engine for gastric cancer research. Key reasons researchers work with us include:

• A thoroughly validated, imaging-ready MFC-luc orthotopic platform with consistently high tumor take rates.
• An immunocompetent syngeneic host setting that is especially well suited to immunotherapy and combination-regimen studies.
• Non-invasive longitudinal bioluminescence imaging that reduces animal usage while capturing early metastatic events.
• Customizable study designs covering dosing routes, schedules, randomization criteria, and endpoint panels.
• An integrated endpoint portfolio spanning in vivo imaging, necropsy, tumor weighing, and histopathology.
• Dedicated project management with scheduled progress updates and clear, audit-ready reporting.

Contact Us

If you are planning a gastric cancer program and need a reliable orthotopic model with quantitative in vivo readouts, contact us today to discuss your project with our scientific team. You can also reach out to Alfa Cytology for a customized proposal, timeline, and quotation — we look forward to supporting your preclinical research with dependable, publication-quality data.

For research use only. Not intended for any clinical use.